NASDAQ:LFCR Lifecore Biomedical - LFCR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lifecore Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.10 +1.43 (+85.63%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.80▼$3.1450-Day Range$1.67▼$7.2652-Week Range$1.52▼$11.96Volume31.58 million shsAverage Volume788,635 shsMarket Capitalization$91.76 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Lifecore Biomedical MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside206.5% Upside$9.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.14Based on 19 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.29) to $0.05 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.81 out of 5 starsMedical Sector787th out of 988 stocksPharmaceutical Preparations Industry378th out of 482 stocks 3.0 Analyst's Opinion Consensus RatingLifecore Biomedical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Lifecore Biomedical has a forecasted upside of 206.5% from its current price of $3.10.Amount of Analyst CoverageLifecore Biomedical has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for LFCR. Previous Next 0.0 Dividend Strength Dividend YieldLifecore Biomedical does not currently pay a dividend.Dividend GrowthLifecore Biomedical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LFCR. Previous Next 2.1 News and Social Media Coverage News SentimentLifecore Biomedical has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Lifecore Biomedical this week, compared to 1 article on an average week.Search Interest23 people have searched for LFCR on MarketBeat in the last 30 days. This is an increase of 5% compared to the previous 30 days.MarketBeat Follows4 people have added Lifecore Biomedical to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lifecore Biomedical insiders have not sold or bought any company stock.Percentage Held by Insiders14.61% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.29) to $0.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lifecore Biomedical is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lifecore Biomedical is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLifecore Biomedical has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lifecore Biomedical (NASDAQ:LFCR) StockLifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Maria, CA.Read More Receive LFCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address LFCR Stock News HeadlinesMarch 20, 2023 | msn.comLifecore Biomedical, Inc. - Common Stock's Return On Capital Employed InsightsMarch 20, 2023 | americanbankingnews.comLifecore Biomedical (NASDAQ:LFCR) Rating Lowered to Equal Weight at StephensMarch 21, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 20, 2023 | americanbankingnews.comStephens Reaffirms Overweight Rating for Lifecore Biomedical (NASDAQ:LFCR)March 18, 2023 | finance.yahoo.comQ2 2023 Lifecore Biomedical Inc Earnings CallMarch 17, 2023 | seekingalpha.comLifecore craters ~60% on 'substantial doubt' as going concern; explores options amid Q2 missMarch 16, 2023 | msn.comLifecore Biomedical Non-GAAP EPS of -$0.24 misses by $0.20, revenue of $38.8M misses by $9.61MMarch 16, 2023 | finance.yahoo.comLifecore Biomedical Reports Second Quarter Fiscal Year 2023 ResultsMarch 21, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 16, 2023 | finance.yahoo.comLifecore Biomedical Announces Intent to Explore Strategic AlternativesMarch 16, 2023 | finance.yahoo.comLifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO RelationshipMarch 14, 2023 | americanbankingnews.comCritical Review: Lifecore Biomedical (LFCR) vs. Its CompetitorsFebruary 16, 2023 | finance.yahoo.comShould You Invest in Lifecore Biomedical (LFCR)?February 7, 2023 | finance.yahoo.comLifecore Biomedical Announces Sale of Curation Foods’ Avocado Products BusinessFebruary 2, 2023 | msn.comLifecore Biomedical to restate financials after finding errorsJanuary 28, 2023 | seekingalpha.comLFCR Lifecore Biomedical, Inc.January 12, 2023 | finance.yahoo.comShould You Hold Lifecore Biomedical (LFCR)?January 11, 2023 | finance.yahoo.comLifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly ReportJanuary 9, 2023 | finance.yahoo.comLifecore Biomedical Raises Capital with Private Placement of Convertible Preferred Stock; Amends Credit FacilitiesDecember 28, 2022 | finance.yahoo.comInvestors in Lifecore Biomedical (NASDAQ:LFCR) have unfortunately lost 47% over the last five yearsDecember 8, 2022 | finance.yahoo.comLifecore Biomedical, Inc. (NASDAQ:LFCR): Are Analysts Optimistic?November 30, 2022 | msn.com$5 Million Bet On Lifecore Biomedical? Check Out These 4 Stocks Insiders Are BuyingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LFCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address LFCR Company Calendar Today3/20/2023Next Earnings (Estimated)4/04/2023Fiscal Year End5/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LFCR CUSIPN/A CIK1005286 Webwww.lifecore.com Phone(800) 454-1355Fax650-368-9818EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$9.50 High Stock Price Forecast$11.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+206.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,430,000.00 Net Margins-36.49% Pretax Margin-20.04% Return on Equity-16.79% Return on Assets-6.38% Debt Debt-to-Equity Ratio0.99 Current Ratio1.40 Quick Ratio0.63 Sales & Book Value Annual Sales$185.79 million Price / Sales0.49 Cash Flow$6.60 per share Price / Cash Flow0.47 Book Value$3.66 per share Price / Book0.85Miscellaneous Outstanding Shares29,600,000Free Float25,272,000Market Cap$91.76 million OptionableOptionable Beta1.11 Key ExecutivesJames G. HallPresident, Chief Executive Officer & DirectorJohn D. MorbergCFO, Secretary & Chief Accounting OfficerKey CompetitorsCorMedixNASDAQ:CRMDVeruNASDAQ:VERUOvid TherapeuticsNASDAQ:OVIDOptiNoseNASDAQ:OPTNY-mAbs TherapeuticsNASDAQ:YMABView All Competitors LFCR Stock - Frequently Asked Questions Should I buy or sell Lifecore Biomedical stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lifecore Biomedical in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LFCR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LFCR, but not buy additional shares or sell existing shares. View LFCR analyst ratings or view top-rated stocks. What is Lifecore Biomedical's stock price forecast for 2023? 1 Wall Street research analysts have issued 12 month price targets for Lifecore Biomedical's stock. Their LFCR share price forecasts range from $8.00 to $11.00. On average, they predict the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 206.5% from the stock's current price. View analysts price targets for LFCR or view top-rated stocks among Wall Street analysts. How have LFCR shares performed in 2023? Lifecore Biomedical's stock was trading at $6.48 at the start of the year. Since then, LFCR stock has decreased by 52.2% and is now trading at $3.10. View the best growth stocks for 2023 here. When is Lifecore Biomedical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023. View our LFCR earnings forecast. What is Lifecore Biomedical's stock symbol? Lifecore Biomedical trades on the NASDAQ under the ticker symbol "LFCR." How do I buy shares of Lifecore Biomedical? Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lifecore Biomedical's stock price today? One share of LFCR stock can currently be purchased for approximately $3.10. How much money does Lifecore Biomedical make? Lifecore Biomedical (NASDAQ:LFCR) has a market capitalization of $91.76 million and generates $185.79 million in revenue each year. The company earns $-97,430,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. How can I contact Lifecore Biomedical? Lifecore Biomedical's mailing address is 2811 AIRPARK DRIVE, SANTA MARIA CA, 93455. The official website for the company is www.lifecore.com. The company can be reached via phone at (800) 454-1355, via email at jeff.sonnek@icrinc.com, or via fax at 650-368-9818. This page (NASDAQ:LFCR) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.